Charles Bennett M.D. Ph.D. M.P.P., Chair of the Center for Economic Excellence in Medication Safety and Efficacy, University of South Carolina presented at the PharmedOut’s 5th Annual Conference on June 12, 2015 at Georgetown University about Fluoroquinolones.

PharmedOut is a Georgetown University Medical Center project that advances evidence-based prescribing and educates healthcare professionals about pharmaceutical marketing practices.

Dr. Bennett presenting at PharmedOut 2015

The Following is a synopsis of Dr. Bennett’s presentation:

Should black box warnings for Fluoroquinolones be revised: Is the bar set too high?

Charles Bennett MD PhD, University of South Carolina The Food and Drug Administration (FDA) has received >150,000 reports of adverse events and 2,400 reports of deaths associated with the generically available Levaquin and ciprofloxacin (two of the three FDA-approved fluoroquinolone antibiotics). Almost half of these reports are associated with psychiatric and neurologic toxicity. The current Black Box label warns of tendonitis, tendon rupture risks, and neurotoxicity occurring among persons with myasthenia gravis; Current product labels provide variable information on psychiatric toxicities. The Southern Network on Adverse Reactions (SONAR) has been investigating these questions for four years, using a novel multi-pronged approach that includes animal studies and, in collaboration with persons who have self-reported quinolone toxicity, a review of FDA adverse event reports Is it time for a revision of the Black Box warnings?

Dr. Bennett asked the question: “Should black box warnings for Fluoroquinolones be revised: Is the bar set too high?” The following is a summary of Dr. Bennett’s conclusions.

1) Conclusion: The FDA’s legal bar related to Black Box Warnings is not too high.

 • Code of Federal Regulations, Title 21, states that adverse events that “may lead to death or serious injury, may be required” to be in a Black Box. Fluoroquinolone antibiotics have adverse events that “may lead to death or serious injury,” including possible Mitochondrial Toxicity, implicated in neurodegenerative diseases, such as ALS, Alzheimer’s, and Parkinson’s.

• Fluoroquinolone antibiotics require a Black Box Warning regarding possible Mitochondrial Toxicity.

2) Conclusion: The Industry Guidance bar related to Black Box Warnings is not too high.

• According to non-binding “Industry Guidance,” Black Boxes may be needed if “there is an adverse reaction so serious in proportion to the potential benefit from the drug (e.g., a fatal, life-threatening or permanently disabling adverse reaction) that it is essential that it be considered in assessing the risks and benefits of using the drug.”

• Fluoroquinolone antibiotics have adverse reactions “so serious in proportion to the potential benefit from the drug (e.g., a fatal, life-threatening or permanently disabling adverse reaction) that it is essential that it be considered in assessing the risks and benefits of using the drug,” including possible Mitochondrial Toxicity, implicated in neurodegenerative diseases, such as ALS, Alzheimer’s, and Parkinson’s.

• Fluoroquinolone antibiotics require a Black Box Warning regarding possible Mitochondrial Toxicity.

3) Conclusion: The legal and Industry Guidance bars are not too high. The problem is that the FDA has failed to do its job regarding Fluoroquinolone antibiotic safety. Specifically, the FDA has failed to act on the 2014 Citizen Petition asking the FDA to add Fluoroquinolone warnings of possible Mitochondrial Toxicity, implicated in neurodegenerative diseases, such as ALS, Alzheimer’s, and Parkinson’s.

Dr. Bennett’s presentation was well received by all who attended.

Following Dr. Bennett’s presentation, John Fratti and Linda Martin, as representatives of the FQ community, were available at the conference to answer questions from the perspective of a ‘floxed’ individual.

Thank You to Linda Martin and John Fratti for attending the conference and representing the FQ community.

Also, a very big Thank You to Dr. Bennett for his ongoing research in addition to his willingness to travel and present findings on Fluoroquinolones to the current academic medical establishment in his pursuit of medication safety. His efforts will ultimately allow patients and medical professional to make more informed and safer healthcare decisions.

Stay vigilant, stay informed, and stay tuned to My Quin Story for true and timely updates on our interactions with the FDA, the Citizen Petitions, and FQ community related research.

Dr Bennett PharmedOut 2

Dr. Bennett presenting at PharmedOut 2015

Bennett-flash

Dr. Bennett

#FDAFail

Share